Synapse - Paul Hamlin

Search Within

Paul Hamlin

Results (293)

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

Journal Article

Kewalramani, T.; Zelenetz, A. D.; Teruya-Feldstein, J.; Hamlin, P.; Yahalom, J.; Horwitz, S.; Nimer, S. D.; Moskowitz, C. H.
British Journal of Haematology (2006)

Fulltext@MSK | Save

Idiopathic cholestatis as a paraneoplastic phenomenon in Hodgkin's lymphoma

Journal Article

Barta, S. K.; Yahalom, J.; Shia, J.; Hamlin, P. A.
Clinical Lymphoma and Myeloma (2006)

Fulltext@MSK | Save

Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: Results of a multicenter phase II experience

Meeting Abstract

O'connor, O.; Wright, J.; Moskowitz, C.; Straus, D.; Portlock, C.; Hamlin, P.; Neylon, E.; Evans, A.; Winter, J.; Gordon, L.; more...
Annals of Oncology (2005)

Fulltext@MSK | Save

Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone anlog BMS 247550 induces major and durable remissions in very drug resistant disease

Meeting Abstract

O'connor, O.; Straus, D.; Moskowitz, C.; Hamlin, P.; Portlock, C.; Gerecitano, J.; Neylon, E.; Colevas, D.; Zelenetz, A.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity

Meeting Abstract

O'connor, O.; Hamlin, P. A.; Neylon, E.; Moskowitz, C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Cortelli, B.; Zelenetz, A. D.; Fleisher, M.; more...
Blood (2005)

Fulltext@MSK | Save

Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-Cell lymphomas: Minimal benefit when analyzed by intent to treat

Meeting Abstract

Horwitz, S.; Moskowitz, C.; Kewalramani, T.; Hamlin, P.; Straus, D.; O'connor, O.; Noy, A.; Portlock, C.; Nimer, S.; Palomba, M. L.; more...
Blood (2005)

Fulltext@MSK | Save

Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin((R))) for elderly high risk patients with untreated DLBCL

Meeting Abstract

Hamlin, P. A.; Moskowitz, C. H.; Wegner, B. C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Dumitrescu, O.; Palomba, M. L.; Horwitz, S. M.; O'Connor, O. A.; more...
Blood (2005)

Fulltext@MSK | Save

Radioimmunotherapy -- Who, what, and when?

Journal Article

Hamlin, P. A.
American Journal of Oncology Review (2005)

Fulltext@MSK | Save

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

Journal Article

O'Connor, O. A.; Wright, J.; Moskowitz, C.; Muzzy, J.; Macgregor-Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; more...
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL

Journal Article

Moskowitz, C. H.; Zelenetz, A. D.; Kewalramani, T.; Hamlin, P.; Lessac-Chenen, S.; Houldsworth, J.; Olshen, A.; Chaganti, R.; Nimer, S.; Teruya-Feldstein, J.
Blood (2005)

Fulltext@MSK | Save